Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients

Food and Chemical Toxicology

Volumn 50, Issue 7, 2012, Pages 2289-2293

  Zhang, Jing ^a   Zhou, Wen ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Cimetidine; Cisplatin; Nephrotoxicity; Organic cation transporter 2; SLC22A2 gene

Indexed keywords

BIOLOGICAL MARKER; CIMETIDINE; CISPLATIN; CREATININE; CYSTATIN C; ORGANIC CATION TRANSPORTER 2;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHINESE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; DRUG EFFECT; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NUCLEOTIDE SEQUENCE; ORGANIC CATION TRANSPORTER 2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; UREA NITROGEN BLOOD LEVEL;

ADULT; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOOD UREA NITROGEN; CHINA; CIMETIDINE; CISPLATIN; CREATININE; CYSTATIN C; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEOPLASMS; ORGANIC CATION TRANSPORT PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 84861449259     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.03.077     Document Type: Article

References (30)

1. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23:460-464.
2. Benohr P., Grenz A., Hartmann J.T., Muller G.A., Blaschke S. Cystatin C-a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press. Res. 2006, 29:32-35.
3. Berns J.S., Ford P.A. Renal toxicities of antineoplastic drugs and bone marrow transplantation. Semin. Nephrol. 1997, 17:54-66.
4. Chen Y., Li S., Brown C., Cheatham S., Castro R.A., Leabman M.K., Urban T.J., Chen L., Yee S.W., Choi J.H., Huang Y., Brett C.M., Burchard E.G., Giacomini K.M. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics 2009, 19:497-504.
5. Ciarimboli G., Deuster D., Knief A., Sperling M., Holtkamp M., Edemir B., Pavenstädt H., Lanvers-Kaminsky C., am Zehnhoff-Dinnesen A., Schinkel A.H. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010, 176:1169.
6. Ciarimboli G., Ludwig T., Lang D., Pavenstädt H., Koepsell H., Piechota H.J., Haier J., Jaehde U., Zisowsky J., Schlatter E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005, 167:1477.
7. de Jongh F.E., van Veen R.N., Veltman S.J., de Wit R., van der Burg M.E., van den Bent M.J., Planting A.S., Graveland W.J., Stoter G., Verweij J. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br. J. Cancer 2003, 88:1199-1206.
8. Dieterle F., Perentes E., Cordier A., Roth D.R., Verdes P., Grenet O., Pantano S., Moulin P., Wahl D., Mahl A., End P., Staedtler F., Legay F., Carl K., Laurie D., Chibout S.D., Vonderscher J., Maurer G. Urinary clusterin, cystatin C, beta 2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat. Biotechnol. 2010, 28. 463-U114.
9. Filipski K.K., Loos W.J., Verweij J., Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 2008, 14:3875-3880.
10. Filipski K.K., Mathijssen R.H., Mikkelsen T.S., Schinkel A.H., Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 2009, 86:396-402.
11. Franke R.M., Kosloske A.M., Lancaster C.S., Filipski K.K., Hu C., Zolk O., Mathijssen R.H., Sparreboom A. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-d-glucosaminidase. Clin. Cancer Res. 2010, 16:4198-4206.
12. Fujita T., Urban T.J., Leabman M.K., Fujita K., Giacomini K.M. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J. Pharm. Sci. 2006, 95:25-36.
13. Fukushima-Uesaka H., Maekawa K., Ozawa S., Komamura K., Ueno K., Shibakawa M., Kamakura S., Kitakaze M., Tomoike H., Saito Y., Sawada J. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab. Pharmacokinet. 2004, 19:239-244.
14. Ito S., Kusuhara H., Yokochi M., Toyoshima J., Inoue K., Yuasa H., Sugiyama Y. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J. Pharmacol. Exp. Ther. 2012, 340:393-403.
15. Kang H.J., Song I.S., Shin H.J., Kim W.Y., Lee C.H., Shim J.C., Zhou H.H., Lee S.S., Shin J.G. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab. Dispos. 2007, 35:667-675.
16. Kawai Y., Nakao T., Kunimura N., Kohda Y., Gemba M. Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. J. Pharmacol. Sci. 2006, 100:65-72.
17. Leabman M.K., Huang C.C., Kawamoto M., Johns S.J., Stryke D., Ferrin T.E., DeYoung J., Taylor T., Clark A.G., Herskowitz I., Giacomini K.M. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002, 12:395-405.
18. Li Q., Liu F., Zheng T.S., Tang J.L., Lu H.J., Jia W.P. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol. Sin. 2010, 31:184-190.
19. Ludwig T., Riethmüller C., Gekle M., Schwerdt G., Oberleithner H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Int. 2004, 66:196-202.
20. Miller R.P., Tadagavadi R.K., Ramesh G., Reeves W.B. Mechanisms of cisplatin nephrotoxicity. Toxins 2010, 2:2490-2518.
21. Pabla N., Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008, 73:994-1007.
22. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33:9-23.
23. Sleijfer D.T., Offerman J.J., Mulder N.H., Verweij M., van der Hem G.K., Schraffordt Koops H.S., Meijer S. The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 1987, 60:2823-2828.
24. Stabuc B., Vrhovec L., Stabuc-Silih M., Cizej T.E. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin. Chem. 2000, 46:193-197.
25. Takimoto, T., Nakabori, T., Osa, A., Morita, S., Terada, H., Oseto, S., Iwazawa, T., Abe, K., 2011. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients. Int. J. Clin. Oncol., Epub ahead of print.
26. + exchanger NHE3. Am. J. Physiol. Cell. Physiol. 2000, 279:C1918-C1924.
27. Vaidya V.S., Ozer J.S., Dieterle F., Collings F.B., Ramirez V., Troth S., Muniappa N., Thudium D., Gerhold D., Holder D.J., Bobadilla N.A., Marrer E., Perentes E., Cordier A., Vonderscher J., Maurer G., Goering P.L., Sistare F.D., Bonventre J.V. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat. Biotechnol. 2010, 28:478-485.
28. Wang Z.J., Yin O.Q.P., Tomlinson B., Chow M.S.S. OCT2 polymorphisms and in-vivo renal functional consequence. studies with metformin and cimetidine. Pharmacogenet. Genomics 2008, 18:637-645.
29. Yokoo S., Yonezawa A., Masuda S., Fukatsu A., Katsura T., Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 2007, 74:477-487.
30. Yonezawa A., Masuda S., Nishihara K., Yano I., Katsura T., Inui K. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (SLC22a2) in the rat. Biochem. Pharmacol. 2005, 70:1823-1831.